Clinical Trials in Eatontown, New Jersey
19 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 1
ENA-001 for Opioid Induced Respiratory Depression
Respiratory Depression
Enalare Therapeutics Inc.36 enrolled3 locationsNCT06967259
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Heart FailureArrhythmiaBradycardia+1 more
Medtronic20,000 enrolled320 locationsNCT00271180
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Treatment Resistant Depression
atai Therapeutics, Inc.142 enrolled48 locationsNCT06524830
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
Stryker Instruments8,000 enrolled2262 locationsNCT03072927
Recruiting
Phase 2
A Study in Subjects With Neurogenic Orthostatic Hypotension
Neurogenic Orthostatic Hypotension
CuraSen Therapeutics, Inc.12 enrolled5 locationsNCT07089043
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
AstraZeneca5,000 enrolled759 locationsNCT06742723
Recruiting
Phase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Heart FailureHeart Failure With Reduced Ejection Fraction
Cytokinetics1,800 enrolled185 locationsNCT06736574
Recruiting
Phase 1Phase 2
Clinical Trials of Multivalent Opioid Vaccine Components
Opioid-use Disorder
New York State Psychiatric Institute45 enrolled2 locationsNCT04458545
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 2
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Chronic Kidney Disease and Hypertension
AstraZeneca218 enrolled71 locationsNCT07222917
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled928 locationsNCT06677060
Recruiting
Phase 2
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
Friedreich Ataxia
Larimar Therapeutics, Inc.85 enrolled8 locationsNCT06447025
Recruiting
Phase 1
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
Excessive Daytime Sleepiness
Centessa Pharmaceuticals (UK) Limited208 enrolled3 locationsNCT07082829
Recruiting
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
ATP-Binding Cassette Subfamily C Member 6 DeficiencyEctonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency
Inozyme Pharma1,000 enrolled14 locationsNCT06302439
Recruiting
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
HyperkalemiaChronic Kidney Disease (Stage 3-4)
AccurKardia, Inc.50 enrolled1 locationNCT07210021
Recruiting
Not Applicable
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
Geographic AtrophyAge-Related Macular Degeneration
VisionCare, Inc.125 enrolled10 locationsNCT05438732
Recruiting
Phase 2
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
Arterial calcificationPseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency+2 more
Inozyme Pharma200 enrolled5 locationsNCT06462547